Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2019 June;44(2) > Minerva Endocrinologica 2019 June;44(2):169-75

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  ACROMEGALY TODAY FOR CLINICAL PRACTICE 

Minerva Endocrinologica 2019 June;44(2):169-75

DOI: 10.23736/S0391-1977.18.02937-1

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Precision medicine in the treatment of acromegaly

Manuel PUIG-DOMINGO 1, 2 , Monica MARAZUELA 3, 4

1 Service of Endocrinology, Germans Trias i Pujol Research Institute and Hospital, Badalona, Spain; 2 Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain; 3 Service of Endocrinology, University Hospital of La Princesa, Madrid, Spain; 4 Department of Medicine, Autonomous University of Madrid, Madrid, Spain



Acromegaly is a chronic disorder usually diagnosed late in the disease evolution, leading to substantial morbidity and mortality related to this long period of undiagnosed state as well as the difficulty in achieving normalization of GH hypersecretion and controlling tumor mass. First generation somatostatin analogues (SSA) are accepted as the first-line medical therapy or as second-line therapy in patients undergoing unsuccessful surgery. However, because a high percentage of patients experience SSA treatment failure, the inclusion of biomarkers associated with a successful or non-successful response to these drug (as well as to all classes of medical therapy) is necessary to better guide the choice of treatment, potentially allowing for a quicker achievement of disease control. The current treatment algorithms for acromegaly are based upon a “trial and error” approach with additional treatment options provided when disease is not controlled. In many other diseases, their therapeutic algorithms have been evolving towards personalizing treatment with medication that best matches individual disease characteristics, using biomarkers that identify therapeutic response, thus allowing the personalization of the therapy. It is time to introduce this approach to acromegaly treatment algorithms. This paper reviews the potential tools for doing so.


KEY WORDS: Precision medicine - Acromegaly - Physicians’ practice patterns

top of page